Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | SHMT2 | P34897 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6078926 | 0.85 | ALDH1A1 (0.50) | PDE5AMEN1KMT2ATDP1SHMT2 | |
| SCHEMBL5252743 | 0.84 | PDE5A (0.42) | PDE5AMEN1KMT2ASHMT2LMNA | |
| SCHEMBL5252659 | 0.71 | ALDH1A1 (0.49) | PDE5AMEN1KMT2ASHMT2ALDH1A1 | |
| SCHEMBL6078683 | 0.67 | MAPT (0.42) | MEN1KMT2ATDP1LMNANPC1 | |
| SCHEMBL6080110 | 0.66 | MAPT (0.42) | MEN1KMT2ATDP1LMNATP53 | |
| SCHEMBL6078798 | 0.65 | MEN1 (0.44) | MEN1KMT2ATDP1LMNATP53 | |
| SCHEMBL6079509 | 0.64 | BLM (0.53) | — | |
| SCHEMBL6078968 | 0.64 | MAPT (0.43) | MEN1KMT2ATDP1LMNATP53 | |
| SCHEMBL5354933 | 0.62 | L3MBTL1 (0.47) | PDE5ALMNATP53NPC1MAPT | |
| SCHEMBL353320 | 0.62 | ROCK1 (0.61) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060100232-A1 | Inhibitors of HIV-1 capsid formation: substituted aryl aminomethyl thiazole ureas and analogues thereof | ACHILLION PHARMACEUTICAL, INC. | 2006-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060100232-A1 | Inhibitors of HIV-1 capsid formation: substituted aryl aminomethyl thiazole ureas and analogues thereof | ZC3HAV1, CD4, ACIN1 | PDE5A 2320/4885MEN1 4767/4885KMT2A 2662/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.